HUMAN FOLLICLE STIMULATING HORMONE RECEPTOR

Abstract: The present invention embraces essentially pure human FSH receptor, or a fragment or mutant thereof which binds FSH, DNA encoding said receptor, fragment or mutant, expression vectors comprising said DNA, cells transfected with said expression vectors, and methods of producing said receptor, fragment or mutant by culturing said transfected cells. The present invention also includes pharmaceutical compositions comprising said receptor, fragment or mutant, as well as methods of treating patients with such compositions to reduce endogenous FSH bioactivity. An improved assay for human FSH using the receptor, fragment or mutant of the present invention is also disclosed.

Description: HUMAN FOLLICLE STIMULATING HORMONE RECEPTOR This application is a continuation-in-part of U.S. Serial Number 07/670,085 filed March 15, 1991, from which priority is claimed. Background of The Invention This invention relates to human follicle stimulating hormone receptor and its synthesis by recombinant DNA techniques. Follicle stimulating hormone (FSH) is a pituitary- derived heterodi eric glycoprotein hormone which shares structural similarities with luteinizing hormone (LH) and thyroid stimulating hormone (TSH), both of which are also produced in the pituitary gland, and chorionic gonadotropin (CG), which is produced in the placenta. The hormones are relatively large (28-38 kilodaltons) and are composed of a common α subunit non-covalently bound to a distinct (5 subunit that confers receptor binding specificity. The cellular receptors for these hormones are known to be members of the G protein-coupled class of membrane- bound receptors which, when activated, stimulate an increase in the activity of adenylyl cyclase. This results in an increase in the level of the intracellular second messenger adenosine 3' ,5'- onophosphate (cAMP), which in turn causes increased steroid synthesis and secretion. Hydropathicity plots of the amino acid sequences of these receptors reveal three general domains: (1) a hydrophilic amino-terminal region, considered to be the amino-terminal extracellular domain, (2) seven hydrophobic segments of membrane-spanning length, considered to be the transmembrane domain, and (3) a carboxy-terminal region which contains potential phosphorylation sites (serine, threonine, and tyrosine residues), considered to be the carboxy-terminal intracellular or cytoplasmic domain. The glycoprotein hormone receptor family is distinguished from other G protein-coupled receptors, such as the 02- adrenergic, rhodopsin, and substance K receptors, by the large size of the hydrophilic amino-terminal domain, which is involved in hormone binding. The FSH receptor is expressed on testicular Sertoli cells and ovarian granulosa cells. While there has been a recognized need for providing essentially pure human FSH receptor, purification of naturally derived preparations is not practical and would not likely be sufficient to permit determination of the amino acid sequence. Recently, one group has cloned the cDNA encoding the rat FSH receptor, deduced the amino acid sequence, and expressed it in mammalian cells (Sprengel, Mol. Endocrinol. 4:525, 1990). Another group, attempting to clone the TSH receptor, apparently also cloned and identified a portion of the transmembrane region of the human FSH receptor (Parmentier, Science 246:1620, 1989). Summary of The Invention The present invention embraces essentially pure human FSH receptor, or a fragment or mutant thereof which binds FSH, DNA encoding said receptor, fragment or mutant, expression vectors comprising said DNA, cells transfected with said expression vectors, and methods of producing said receptor, fragment or mutant by culturing said transfected cells. The present invention also includes pharmaceutical compositions comprising said receptor, fragment or mutant, as well as methods of treating patients with such compositions to reduce endogenous FSH bioactivity. An improved assay for human FSH using the receptor, fragment or mutant of the present invention is also disclosed. Brief Description of The Drawings Figure 1 is a map of the human FSH receptor cDNA clones. A partial restriction endonuclease map is shown which was determined by combining DNA sequence data derived from portions of each of the five clones. Size increments of 0.2 kilobase pair (kb) are marked. The regions to which the clones correspond are indicated by the solid lines below the restriction endonuclease map. The clone designation and the approximate size in kb are indicated to the left and right of each solid line, respectively. Approximate locations of the amino-terminal extracellular domain, transmembrane domain, and carboxy-terminal intracellular domain of the encoded protein are indicated by the dashed arrows above the restriction endonuclease map. The position of an insertion (probably an intron or a portion of an intron) in the 5-10 clone is indicated by the open box. Figures 2A and 2B depict the strategy used for engineering a "full-length" human FSH receptor cDNA for the purpose of expression of the encoded protein in a mammalian cell line. Figure 3 is a diagram of the expression vector plasmid used to develop CHO-DUKX cell lines stably transfected with the human FSH receptor. Figure 4 is a diagram of the expression vector plasmid used to develop Yl cell lines stably transfected with the human FSH receptor. Figure 5 illustrates intracellular cAMP levels measured in the CHO-DUKX cell line CHOHFSHR4Q- 3, after treatment with varying doses of either FSH (circles), or LH (triangles). Each point represents the mean value. Standard errors are shown by the vertical bars. Figure 6 illustrates progesterone levels measured in the culture medium of the Yl cell line Y1HFSHR4-38, after treatment with varying doses of FSH. Vertical bars depict the standard error in the progesterone measurements at each FSH dose. Detailed Description of the Invention As used herein, human FSH receptor, and its FSH- binding fragments or mutants, refers to polypeptides which are capable of recognizing and selectively binding with human FSH and which produce no significant immunological response in humans. Thus, the present invention includes human FSH receptor having the amino acid sequence depicted in Sequence ID No:2, as well as FSH-binding fragments or mutants thereof which retain a very high degree of homology (i.e. at least 95% identity) with the depicted amino acid sequence, or with at least the extracellular portion thereof. Fragments of the human FSH receptor embraced by the present invention include those fragments remaining after the cytoplasmic and/or the transmembrane domains have been deleted from the full polypeptide. An especially preferred fragment embraced by the present invention is the amino-terminal extracellular portion comprising approximately amino acids 1 to 349 of the human FSH receptor amino acid sequence shown in Sequence ID No:2. Since some of the loops which span the transmembrane regions (listed in features section. Sequence ID No:2) are also extracellular, these may be linked (e.g. through appropriate spacer molecules) to a fragment containing the amino-terminal extracellular portion to improve binding. The polypeptide may be glycosylated, as in the natural receptor, or may be partially or completely deglycosylated. It is further contemplated that only a portion of the above-described amino-terminal extracellular domain may be effectively utilized to bind FSH since it is very likely that the complete extracellular domain is not necessary for this purpose. Thus, a fragment which is somewhat shorter than the 349 amino acids of the complete extracellular domain may be readily produced and tested for effective binding to FSH. So long as the FSH-binding region of the extracellular portion is maintained intact, the length of the overall fragment utilized is not critical. For this reason, it is also expected that non-interfering amino acids can be added to either end of the extracellular domain, or FSH-binding fragment thereof, without adversely affecting the FSH-binding capacity of the polypeptide. Accordingly, this invention embraces a fragment of the human FSH receptor which comprises a substantial portion of the extracellular domain and which retains substantially the same FSH-binding characteristics as the complete extracellular domain. Mutant forms of the above-described receptor and fragments are also within the scope of the present invention. Such mutants include conservative substitutions in one to ten amino acid residues, the location and nature of such substitutions being selected so as not to significantly degrade the FSH-binding characteristics of the receptor or fragment thereof which is modified. Essentially pure human FSH receptor, or a fragment or mutant thereof, is prepared by isolating and cloning the DNA encoding it from a cDNA or genomic library, ligating the DNA into a vector, transfecting host cells with the vector, culturing transfected host cells under conditions which permit expression of the receptor, fragment or mutant, and recovering the receptor, fragment or mutant from the culture. The DNA which is used to make expression vectors may be genomic DNA or cDNA encoding human FSH receptor, and may contain regions which enhance expression, such as introns, promoters, enhancers, etc. The DNA may be readily modified by substitution, deletion or insertion of nucleotides (e.g. by site-specific mutagenesis) that do not adversely affect the biological or FSH-binding activity of the expressed protein. For example, conservative substitutions (mutations) which alter from one to ten amino acids may be made without adversely affecting the overall structure and activity of the expressed protein (mutein). Likewise, certain portions of the DNA, such as those portions which code for the cytoplasmic and/or transmembrane domains, may be deleted so that only a fragment, such as the soluble extracellular domain, of the protein is expressed. The human FSH receptor or FSH-binding fragment or mutant thereof may also be expressed as a fusion protein. One such fusion protein would include a polypeptide at the carboxy-terminus which would confer characteristics which would facilitate purification of the protein, or immobilization of the purified protein on a solid substrate for use in FSH assays or FSH purification protocols. Another such fusion protein would include a cleavable polypeptide at the amino-terminus which would facilitate expression. Human FSH receptor produced in accordance with the present invention is essentially pure, meaning that it is substantially free of biological adventitious agents normally associated with FSH receptor extracted from natural sources, such as, for example, bacteria, viruses, and other proteins. The receptor may be formulated into pharmaceutical compositions by mixing with suitable pharmaceutically acceptable carriers in a manner known to those skilled in the art. Generally, pharmaceutical compositions may be formulated for oral, parenteral (including subcutaneous, intramuscular, and intravenous), vaginal, rectal, buccal (including sublingual), transdermal or intranasal administration. Compositions for parenteral administration are normally in the form of a liquid solution, dispersion, or emulsion, preferably isotonic; for vaginal or rectal administration, as a cream or suppository; for oral or buccal administration, as a tablet or capsule; and for intranasal administration, as a powder, nasal drop or aerosol. Various slow release, depot implant or injectable dosage forms may be utilized. The active component may also be incorporated into polymer matrices, liposo es and microspheres to control delivery. These compositions may conveniently be administered in unit dosage form and may be prepared by any of the methods well-known in the pharmaceutical art. Formulations for parenteral administration may contain as common excipients sterile water or saline, alkylene glycols such as propylene glycol, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, hydrogenated naphthalenes and the like. Formulations for vaginal or rectal administration, e.g. suppositories, may contain as excipients, for example, polyalkyleneglycols, vaseline, cocoa butter, and the like. Formulations for nasal administration may be in powder form and contain as excipients, for example, lactose or dextran, or may be aqueous or oily solutions for administration in the form of nasal drops or metered spray. For buccal administration, typical excipients include sugars, calcium stearate, pregelatinated starch and the like. One or more surfactant acids or salts can be added to the solution or powder formulation. Suitable pharmaceutically acceptable surfactant salts will be those which retain the phenomenon of enhanced peptide absorption, as well as the compound's surfactant characteristics and which are not deleterious to the subject or otherwise contraindicated. The dosage of active ingredient administered, as well as the route and frequency of administration, will obviously depend upon the needs and condition of the patient being treated, the therapeutic effect which is sought, and the judgement of the doctor conducting the treatment. Pharmaceutical compositions comprising human FSH receptor, or FSH-binding fragments or mutants thereof, may be administered to a patient in therapeutically effective doses to bind with endogenous circulating FSH in the patient and thereby control the available level of bioactive FSH. Thus, pharmaceutical compositions of the present invention are effectively utilized to reduce endogenous FSH bioactivity. In a female patient, such treatment may be effectively used to prevent follicle growth and maturation, thereby preventing pregnancy. In a male patient, such treatment may be effectively used to prevent sper atogenesis. A particularly suitable pharmaceutical composition for the above purpose comprises a fragment of the human FSH receptor which comprises the amino-terminal extracellular domain or a substantial portion thereof with substantially the same FSH-binding characteristics. Essentially pure human FSH receptor may also be advantageously utilized in conventional receptor assays for FSH, such as, for example, that disclosed in Reichert, Endocrinology 94:483, 1974. Substitution of the pure receptor of the present invention, or a fragment thereof which binds FSH, will substantially improve the consistency and performance of such assays. A fragment comprising the amino-terminal extracellular domain or an FSH-binding fragment and/or fusion protein thereof can also be linked to an affinity column to purify FSH from fluids, extracts, etc. The receptor can be incorporated into a stable cell line, preferably a eukaryotic cell line, and most preferably a mammalian cell line, which is capable of producing a measurable biological response upon stimulation of the receptor. Measurement of cell response in the presence of FSH under assay (e.g. in test serum, plasma, culture media, tissue homogenates, etc.) would provide an indication of bioactivity, and thereby provide a highly useful diagnostic assay. Such a cell line could also be used to screen chemical libraries for substances that may interact with the FSH receptor or to test peptides or small proteins for their ability to bind to the FSH receptor in a rapid through-put screening system. An example of a rapid through-put screening system is one in which the binding of a ligand to the recombinant FSH receptor results in the production or blockage of production of a measurable product such as CAMP or progesterone. Such a system could be further enhanced by operatively linking an easily measured marker element such as one which produces bioluminescence (e.g. the luciferase gene) to the receptor signal transduction pathway (e.g. by using the cAMP response element). Essentially pure human FSH receptor or FSH-binding fragments or mutants thereof can also be used in X-ray crystallographic analysis to develop molecular models. Such models are useful in defining the tertiary structure of the hormone-binding domains of the human FSH receptor. Such information would provide insight into the structure of the actual regions of contact between FSH and its receptor, thus aiding the design of peptides which have FSH agonistic or antagonistic activity. The recombinant techniques suitable for producing the proteins and DNA of the present invention, including identification of suitable mutation techniques, vectors, host cells, culture conditions, etc., are well-known to those skilled in the art and are adequately described, for example, in US 4,761,371 and WO 88/09818, the disclosures of which are incorporated herein by reference. The experimental protocols, bacterial and bacteriophage culture media and chemical solutions used in the examples below are described in detail in Sambrook, "Molecular Cloning: A Laboratory Manual," 2nd ed.. Cold Spring Harbor Laboratory Press, 1989, unless otherwise referenced. Example 1. Isolation and Characterization of Human FSH Receptor cDNA Clones Library screening. A rat FSH receptor cDNA clone similar to that described by Sprengel, Mol. Endocrinol. 4:525, 1990 was obtained from Dr. William Moyle, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School. This cDNA clone was inserted into the SV40 late expression vector pSVL (Pharmacia LKB, product number 27-4509-01) and was designated pSVLFSHR. A 2.1 kb DNA fragment containing the region corresponding to the complete rat FSH receptor protein coding region was excised from the plasmid using the restriction endonuclease sites Xb l and BamHI. The digested DNA was size-fractionated by gel electrophoresis, and the 2.1 kb rat FSH receptor fragment was purified by electroelution from the gel. This purified DNA fragment was used as a probe for library screening to identify human FSH receptor cDNA clones. A lambda gtll cDNA library, constructed from RNA extracted from human testis, was purchased from Clontech, Palo Alto, CA (catalogue number HLlOlOb) and was amplified prior to use. Twenty aliquots of the amplified library, equivalent to approximately 7.5 x 10^ plaque forming units (pfu), were each adsorbed to about 0.5 milliliters (ml) of a plating suspension of E. coli strain Y1088. The suspension had been prepared by growing an overnight culture of Y1088 at 37°C in NZYM or LB supplemented with 0.2% maltose and 10 illimolar (mM) MgSθ4, pelleting the cells, and then resuspending them in 10 mM MgSθ4 to an O.D.gQO of °- 5 - About 6.5 ml of molten NZYM top agarose (0.7%), at a temperature of 48°C, was added to each phage/cell suspension and the resulting mixture was poured onto one of twenty 150 millimeter (mm) NZYM agar plates (prewar ed to 42°C). The total number of phage plated for the primary screen was about 1.5 X 10 * ->. After a 4 hour incubation at 42°C, followed by chilling at 4°C for several hours, duplicate nitrocellulose filter (Millipore) plaque lifts were generated from each plate according to the procedures of Benton and Davies (Science, 196:180, 1977). The random oligonucleotide priming procedure of Feinberg and Vogelstein (Anal. Biochem. 137:266, 1983) was used to generate, from the template rat FSH receptor DNA fragment described in the preceding paragraph, a 32 P-labeled probe of a specific activity of 1-2 X 10 9 counts per minute (cpm)/microgram {μg) . Prehybridization of the nitrocellulose filter phage lifts was done in a buffer containing 50% formamide, 5X SSC [IX SSC is 0.15 molar (M) sodium chloride, 0.015 M sodium citrate], 20 mM sodium phosphate buffer, pH 7.2, 10X Denhardt's reagent (50X Denhardt's reagent is 1% Ficoll, 1% polyvinylpyrrolidone and 1% bovine serum albumin) and 100 μg/ml tRNA at 37°C for about 6 hours. Hybridization of the filters was done in the same buffer except that the rat FSH receptor DNA probe was added at a concentration of about 3 X 10 6 cpm/ml buffer. After hybridization for 16-24 hours at 37°C, excess probe was washed from the filters in 2X SSC, 0.1% SDS at room temperature for 30 minutes, then 0.2X SSC, 0.1% SDS at 37°C for 60 minutes. The filters were subsequently exposed to XAR film (Kodak) overnight at -70°C. Six duplicate positives were identified from the primary library screen. With the wide end of a pasteur pipette, plaque-containing agar plugs were removed from the 150 mm plates in the regions in which the positive clones were located. The phage were eluted by soaking the plugs in SM. The suspended phage were then replated onto 150 mm NZYM agar plates as described for the primary screen. Plates which contained about 500 pfu per plate were selected for secondary screening. The procedures used for filter lifts and filter hybridizations for the secondary screen were the same as described for the primary screen. Following the secondary screen, 5 putative human FSH receptor positives were identified and isolated as purified λgtll bacteriophage clones. They were assigned the following designations: 1-5, 5-10, 11-11, 13-9, and 15-6. Determination of the DNA sequences of the putative human FSH receptor cDNA clones. Bacteriophage DNA was prepared from each of the λgtll cDNA isolates using the plate lysate method described in Sambrook, "Molecular Cloning: A Laboratory Manual," 2nd ed.. Cold Spring Harbor Laboratory Press, 1989, page 2.118. The bacteriophage DNA was digested with EcoRI restriction endonuclease, and then size-fractionated in an agarose gel for purification of the cDNA insert fragments. The purified cDNA inserts were subcloned into the EcoRI site of pUClθ in order to facilitate subsequent cloning and sequencing manipulations. Double-stranded plasmid DNA was purified from 5 ml cultures of the host strain E. co i MC1061 by the small-scale alkaline lysis method (Sambrook, ibid. p. 1.25), then further purified by passage over Elutip-d columns (Schleicher & Schuell, Keene, NH) using the manufacturer's protocol. Half of the plasmid DNA obtained from each small-scale plasmid preparation was then denatured in 0.2 normal NaOH, 0.2 mM EDTA in a volume of 20 microliters (μl ) at room temperature for 10 minutes. The denatured plasmid DNA was neutralized and ethanol precipitated by adding 7.5 μl of 7.5 M ammonium acetate and 110 μl 100% ethanol and chilling the mixture in liquid nitrogen. The DNA precipitate was pelleted by centrifugation in a microfuge for 10 minutes. The DNA pellets were washed in 70% ethanol and dried. Sequencing reactions were done with Sequenase T7 DNA polymerase (United States Biochemical) according to the manufacturer's specifications. Preliminary sequencing reactions were done with forward and reverse sequencing primers (Pharmacia LKB) for the pUC18 polylinker region. Data generated from preliminary sequencing was used to design human FSH receptor-specific sequencing primers. The primers were either synthesized on a model 391 Applied Biosystemβ DNA synthesizer or ordered from National Biosciences, Inc., Hamel, MN. Some DNA sequence data was obtained by subcloning smaller restriction endonuclease fragments of the original clones into pUClδ and repeating sequencing reactions with the forward and reverse primers. Preliminary sequence data showed that none of the five cDNA isolates represented the full-length protein coding region of the human FSH receptor, but that the combined sequence data from the clones could be used to infer the complete protein sequence. A schematic diagram of the relative locations of each of the five clones in relation to a map of the complete human FSH receptor cDNA sequence is shown in figure 1. The complete human FSH receptor cDNA sequence, obtained by combining the sequence readings from the overlapping clones using the Genetics Computer Group (GCG) fragment assembly computer program, is depicted in Sequence ID No:l and the inferred amino acid sequence is depicted in Sequence ID No:2. Analysis of the human FSH receptor DNA sequence resulted in the identification of a long open reading frame of 2085 nucleotides which encoded a protein of 695 amino acids. The human FSH receptor is therefore 3 amino acids longer than the rat FSH receptor. The overall percent identities between the rat and human FSH receptor DNA and protein sequences were determined using the GCG Bestfit program and were 87% and 90%, respectively. The extracellular amino- terminal hydrophilic portion of the human FSH receptor is estimated to be 349 amino acids in length, and shares 87% identity with the corresponding region of the rat FSH receptor. The seven membrane spanning regions of the two species, which are bridged by three extracellular and three intracellular loops, share 95% identity, and the carboxy- terminal intracellular regions share only 81% identity. The partial amino acid sequence published by Parmentier, Science 246:1620-1622, 1989, corresponds to amino acids 399 to 525 in Sequence ID No:2. Clone 5-10 was a variant in that it contained an insertion of 0.25 kb after the T at nucleotide position 448 in Sequence ID No:l. The DNA sequence of the insertion was not similar to any portion of the rat or human FSH receptor DNA sequence and also was not similar to any known sequence in the Genbank or EMBL DNA sequence databases. The corresponding region in clone 11-11 did not contain this insertion. LH receptor cDNA clones isolated from a human thyroid cDNA library contain similar variations (Frazier, Mol. Endocrinol. 4:1264-1276, 1990). These variants are likely derived from incompletely and/or aberrantly spliced mRNA molecules. The presence of a 3' splice consensus sequence (CAG'G) at the 3' junction of the 5-10 insertion is evidence which supports this explanation. The pUC18 plasmids harboring the 11-11 (called pHFSHRll-11) , 15-6 (called pHFSHRl5-6), and 5-10 (called pHFSHR5-10) cDNA inserts were deposited with the American Type Culture Collection (ATCC), Rockville, MD, on March 1, 1991 and have received the accession numbers ATCC68538, ATCC68540, and ATCC68539, respectively. These deposits were made in accordance with all of the requirements of the Budapest Treaty. Example 2. Construction of vectors for the expression of the full-length human FSH receptor in mammalian cells. The strategy for engineering a human FSH receptor DNA construct for expression in mammalian cells is shown in Figures 2A and 2B. Refering to Figure 2A, the 5' 691 base pair (bp) Nsil-BamHl fragment which contained the start ATG was purified from pHFSHRll-11 and subcloned into pUClβ digested with PstI and BamHI. The resulting plasmid, pHFSHRll-llnb, was linearized with Sphl. The termini were blunted by treatment with the Klenow fragment of DNA polymeraεe I (New England Biolabs, Beverly, MA). After ligation of Xhol linkers (New England Biolabs, Beverly, MA) to the blunted termini, the mixture was digested with Xhol and BamHI and the approximately 700 bp human FSH receptor 5' fragment was gel purified. A fragment from the middle region of the human FSH receptor cDNA was isolated from pHFSHRll-11 by digestion with BamHI and Sphl and gel purification of the appropriate 734 bp piece. The 3' human FSH receptor fragment, which contained the TAA stop codon, was isolated from pHFSHRl5-6 by first digesting the plasmid with Drain, then blunting the termini in a reaction with T4 DNA polymeraεe. Xhol linkers were ligated to the blunted ends and the resulting mixture was digested with Sphl and Xhol and the 3' 690 bp (approximately) Sphl-Xhol fragment was isolated and purified. Refering to Figure 2B, the 5' 700 bp XhoI-BamHI and middle 734 bp BamHI-SphI human FSH receptor cDNA fragments were subcloned into pUCl8-XhoI (created in this laboratory by converting the Smal site in the pUC18 polylinker to an Xhol site with Xhol linkers) digested with Xhol and Sphl. The resulting plasmid, pHFSHR1.4xs, was digested with Xhol and Sphl. The digested DNA was size-fractionated by electrophoresis in a 5-6% polyacrylamide gel and the approximately 1400 bp fragment containing the 5' and middle regions of the human FSH receptor cDNA was excised and purified by electroelution. The 3' Sphl-Xhol fragment, which contains the TAA stop codon, was subcloned into pUClδ-XhoI digested with Sphl and Xhol. The resulting plasmid, pHFSHR675sx, was digested with Sphl and EcoRI. The digested DNA was fractionated in a 5-6% polyacrylamide gel and the approximately 700 bp piece was excised and purified by electroelution. The complete human FSH receptor coding region was assembled by combining the 5' 1400 bp XhoI-SphI fragment with the 3' 700 bp Sphl-EcoRI fragment in a ligation with pUC18-XhoI digested with Xhol and EcoRI. Correct assembly of the construction, called pHFSHRX, was verified by restriction endonuclease digestion and DNA sequencing. The completely engineered human FSH receptor 2.1 kb Xhol fragment, which contains approximately 18 bp of 5' noncoding sequence and 12 bp of 3' noncoding sequence in addition to the entire human FSH receptor protein coding region, was excised from pHFSHRX by Xhol digestion. The digested DNA was size-fractionated by electrophoresis in a 0.7% agarose gel. The 2.1 kb Xhol fragment was excised from the gel, purified by electroelution in a Little Blue Tank™ (ISCO) using the procedure recommended by the manufacturer, and inserted into the Xhol cloning sites of the mammalian cell expression vector plasmids. Plasmids containing the insert in the appropriate orientation for human FSH receptor mRNA transcription were selected by restriction endonuclease fragment analysis. Prior to introduction into mammalian cells, expression vector plasmid DNA was purified either by two sequential high-speed centrifugations through cesium chloride density gradients, or by using the plasmid maxi kit (Qiagen, Chatsworth, CA) according to the manufacturer's protocol. Any suitable mammalian cell expression vector can be used for the expression of the human FSH receptor. The necessary vector plasmid components include the following: a eukaryotic promoter such as the mouse metallothionein I (MMT-I) promoter, Rous Sarcoma Virus promoter, or simian virus 40 early or late promoters for driving transcription of the human FSH receptor mRNA; a marker gene such as the neomycin resistance gene (Neo), dihydrofolate reductase (DHFR) gene, or multidrug resistance gene (MDR) for the selection of transfected cells; a polyadenylation signal (poly A), such as the SV40 early polyadenylation region for the 3' processing of the receptor RNA transcript; and a bacterial origin of replication and antibiotic resistance gene such as the pBR322 ori and the ampicillin resistance gene, to enable growth and propagation of the vector plasmid in a suitable E. coli strain. For some cell lines, it may be important to include an intron in the region which is transcribed into human FSH receptor encoding mRNA. It is preferable to place the intron between the promoter and the human FSH receptor cDNA insert, thereby positioning it in the 5' untranslated region of the human FSH receptor RNA transcript. Any suitable intron can be used. The intron used in our experiments was a 2 kb Xbal-PstI portion of intron A in the human glycoprotein α subunit gene (Fiddes, J. Mol. Appl. Genet. 1:13, 1981). In the expression vectors, it was inserted between the the MMT-1 promoter region and the human FSH receptor cDNA fragment. The truncated intron retained the endogenous splice acceptor, but the splice donor was supplied by a synthetic oligonucleotide. A diagram of the human FSH receptor expression vector used for CHO cell transfections, pDαHFSHRX (human FSH receptor in CLH3AXSV2DHFRhαIVS) , is shown in Figure 3 and a diagram of the human FSH receptor expression vector used to stably transfect Yl cells, pNαHFSHRX (human FSH receptor in CLH3AXSV2NEOhαIVS) , is shown in Figure 4. The MMT-I gene sequences (nucleotide numbers 4542-7514 in Figure 3, nucleotide numbers 5192-8164 in Figure 4) which include the promoter region, are the same as those shown upstream of the Xhol site in the construction of CLH3X (Reddy, DNA 6:461, 1987). The human glycoprotein α subunit gene intron A fragment, described in the preceding paragraph, is located between nucleotide numbers 7514 and 9514 in Figure 3, and between nucleotide numbers 8164 and 10164 in Figure 4. Downstream of the Xhol site, the MMT-I introns and polyadenylation signal sequences were removed and replaced with the SV40 early polyadenylation region (nucleotide numbers 11614-11857 in figure 3, nucleotide numbers 12264- 12508 in figure 4). The pML region (Lusky, Nature 293:79, 1981) contains the bacterial origin of replication and ampicillin resistance gene from pBR322 (nucleotide numbers 1925-4542 in Figure 3, nucleotide numbers 2575-5192 in Figure 4). The DHFR gene transcription unit (nucleotide numbers 1 to 1925 in Figure 3), which includes the mouse DHFR cDNA and the SV40 early region promoter, small T intron and early region polyadenylation sequences, corresponds to the PvuII-BamHI fragment in pSV2DHFR (Subramani, Mol. Cell. Biol. 1:854, 1981). The PvuII site was converted to a BamHI site prior to insertion of the fragment into the expression vector plasmid. The neo gene transcription unit (nucleotide numbers 1-2575 in figure 4) was assembled by replacing the DHFR cDNA (nucleotide numbers 342-1077 in Figure 3) with a 1385 bp Hindlll-Smal fragment from pSV2-neo (Southern, J. Mol. Appl. Genet. 1:327, 1982). The Smal site was converted to a BamHI site prior to insertion of the fragment into the expression vector plasmid. The plasmid pNαhFSHRX can be used to transfect most continuous mammalian cell lines, and was deposited with the ATCC on November 19, 1991, as accession number ATCC68833. The deposit was made in accordance with all of the requirements of the Budapest Treaty. The plasmid pDαhFSHRX is best suited for the transfection of cell lines which lack dihydrofolate reductase (DHFR) activity. DNA cloning and engineering techniques can be used by those skilled in the art to modify the human FSH receptor DNA expression construction so that FSH-binding fragments are encoded. These modified DNA fragments can be inserted into expression vectors such as those described herein and used to transfect mammalian cells to develop lines which secrete soluble FSH-binding fragments of the human FSH receptor, such as the amino terminal extracellular domain or an FSH-binding fragment thereof. Example 3. Development of Mammalian Cell Lines which Stably Express a Functional Human Recombinant FSH Receptor or an FSH-binding fragment or mutant thereof. Suitable mammalian cell lines for expression of recombinant human FSH and its derivatives include Chinese Hamster Ovary (CHO), mouse adenocarcinoma Yl, rat pituitary GH3, human breast carcinoma MCF7, and human embryonic kidney 293. In this example, the use of Yl and CHO cells is described. Yl cells are a clonal steroid secreting cell strain initiated from a mouse adrenal cortex tumor (Yasumura, Cancer Res. 26: 529-536, 1966). These cells were obtained from the ATCC cell bank (ATCC CCL 79) and were maintained in culture by growth in Ham's FlO medium supplemented with 15% horse serum (HS), 2.5% FBS, and 1% L-glutamine (Yl growth medium) . CHO-DUKX cells are a clonal mutant of Chinese hamster ovary cells lacking dihydrofolate reductase activity (Urlaub G. and Chasin, L.A. PNAS 77: 4216-4220, 1980). The cells were maintained in Minimum Essential Medium Alpha (MEM-α) supplemented with 10% FBS and 1% L-glutamine (CHO growth medium) . All cell culturing was done at 37°C in a 5% CO2, humidified atmosphere. Calcium phosphate transfections. The transfection protocol used was a modification of a published method (Graham, Virology 52: 456, 1973). Approximately 24 hours prior to transfection, cells were plated in 100 mm diameter dishes at a density of 7 X 10 5 cells/dish (CHO-DUKX) or 1 X 10 6 cells/dish (Yl). For transfections, 10 μg of the vector plasmid DNA (pDαHFSHRX for CHO-DUKX cells, pNαHFSHRX for Yl cells) was added to 0.5 ml of transfection buffer. Transfection buffer was prepared by combining 4 grams (g) NaCl, 0.185 g KCl, 0.05 g Na2HP04, 0.5 g dextrose, and 2.5 g HEPES in sterile, distilled water and adjusting the volume to 500 ml, and the pH to 7.5. To the DNA/transfection buffer mixture was added 31 μl of 2 M CaCl2« The solution was mixed using a vortex mixer and allowed to stand at room temperature for 45 minutes to allow the DNA precipitate to form. The DNA precipitate was layered over the cells after removal of the culture medium. After 20 minutes at room temperature, 5 ml of the appropriate growth medium was added and the cells were cultured for 6 hours. The medium was removed and the cells shocked for 3.5 minutes in 3-4 ml of transfection buffer containing 15% glycerol. The cells were rinsed twice with phosphate buffered saline prior to the addition of 10 ml growth medium. Approximately 48 hours post transfection, the CHO-DUKX cells were subcultured at a 1:10 split ratio and selection medium was added. Yl cells were allowed to grow for 72 hours post transfection before subculturing at a 1:5 split ratio in selection medium. Selection medium for CHO-DUKX cells consisted of MEM-α without ribonucleosides and deoxyribonucleosides supplemented with 10% dialyzed FBS, 1% L-glutamine, and 0.02 μlΛ methotrexate (MTX). Selection medium for Yl cells consisted of Yl growth medium with 80 g/ml G418. MTX- resistant CHO-DUKX cell colonies and G418-resistant Yl cell colonies formed after approximately 2 to 3 weeks, and were individually picked and cultured until cell numbers were sufficient for cryopreservation and testing for hormone responsiveness. Demonstration of Human Recombinant FSH Receptor Bioactivity in Stably Transfected CHO Cells. To determine if the engineered human FSH receptor cDNA construct could produce a protein that was biologically functional in stably transfected CHO cells, the MTX- resistant CHO cell colonies were treated with human recombinant FSH and intracellular cAMP levels were measured. For the cAMP assay, the cells were subcultured in 12 well plates at a density of 2.5 X 10 4 cells/well in CHO cell selection medium. After 72 hours of culture, each well was washed with 1.5 ml of warm growth medium. To each washed well was added 300 μl of serum-free growth medium containing 0.1 mM 3-isobutyl-l-methylxanthine (Sigma). After 15 minutes of culture, human recombinant FSH was added to the medium in each well so that the final concentration was approximately 335 ng (2413 mlU) per ml. After 30 minutes of culture, the assay was terminated by subjecting the cells to four rapid freeze-thaw cycles. A 50 μl aliquot of each cell lysate was transferred to a 1.5 ml tube for determination of protein content. Cold ethanol (300 μl ) was added to each remaining lysate sample before transfer to separate 1.5 ml tubes. All lysate samples were centrifuged at 13,000 X g for 15 minutes to remove cell debris. Determination of total soluble protein was done with a protein assay kit purchased from Bio-Rad (catalog number 500-0002) using the protocol supplied by the manufacturer. The ethanol-treated lysate samples were freeze-dried in aliquots of 5-100 μl , and resuspended in 100 μl of the assay buffer provided in the Dupont/NEN Medical Products cAMP assay kit (catalog number NEK-033). The cAMP content of the resuspended lysate samples was determined using the acetylated radioimmunoassay protocol supplied with the kit. The samples were not diluted for the assay. In the majority of the human FSH receptor- transfected CHO cell lines, higher intracellular cAMP levels were measured after FSH stimulation than in the controls (untransfected CHO-DUKX cells and CHO-DUKX cells transfected with CLH3AXSV2DHFRhc_IVS) . The average response ' was about 16-fold that of the controls. One nonclonal cell line, CHOHFSHR4Q-13, was chosen for a hormone dose response analysis. The procedure used was the same as in the preceding paragraph, except that the cells were treated with either human recombinant FSH or LH in concentrations ranging from 0-10,000 mlU/ml. Each dose was analyzed in triplicate. The amount of intracellular cAMP produced was expressed in nanomoles (n ole) per milligram (mg) of soluble protein and plotted versus FSH or LH concentration to generate dose response curves. The FSH and LH dose response curves are shown in Figure 5. The results show that the CHOHFSHR4Q-13 CHO cell line displayed a saturable increase in intracellular cAMP in response to FSH stimulation but not in response to LH stimulation. Half-maximal FSH stimulation (ED50) occurred at a dose of 144 mlU/ml FSH. The human FSH receptor cDNA therefore can be used to produce a biologically functional human FSH receptor protein in CHO cells, enabling the cells to mediate a specific cAMP response to FSH and not LH. The human FSH receptor content of the CHOHFSHR4Q-13 line, or a similar line which produces the human recombinant FSH receptor or FSH-binding fragments or mutants thereof, may be increased by exposing the cells to stepwise increases in MTX concentration. This causes amplification of DHFR cDNA copy number along with linked sequences which include the human FSH receptor cDNA, indirectly increasing synthesis of the encoded proteins. This may be done, if necessary, to increase the sensitivity of the bioassay. Also, mammalian cells which express high levels of human FSH receptor or FSH-binding fragments or mutants thereof, can be used for the manufacture of large amounts of human FSH receptor protein for use as therapeutics or in receptor radioimmunoassays. The CHOHFSHR4Q-13 line, or a similar line, may also be used in an assay for estimating the in vitro bioactivity of pharmaceutical preparations containing FSH, or FSH-like substances. A reporter gene such as luciferase, can be operatively linked to a cAMP response element, and increases in cAMP levels may be indirectly measured by a non-radioactive method, such as bioluminescence, to provide a measurement of FSH bioactivity. The CHOHFSHR4Q-13 line was deposited with the ATCC on November 19, 1991, as accession number ATCC CRL 10921. The deposit was made in accordance with all the requirements of the Budapest Treaty. Demonstration of Recombinant Human FSH Receptor Bioactivity in Stably Transfected Mouse Adrenal Yl Cells. To determine if the engineered human FSH receptor cDNA construct could produce a protein that was biologically functional in stably transfected Yl cells, the G418- resistant Yl cell colonies were treated with human recombinant FSH and the culture media analyzed for progesterone content. For the progesterone assay, the cells were subcultured in 6 well plates (35 mm well diameter) at a density of 4 X 10 5 cells/well in Yl cell selection medium. After two days of culture, the Yl cell selection medium was removed and replaced with 3 ml Ham's FlO medium supplemented with 5% horse serum, 0.8% fetal bovine serum, 1% L-glutamine, and 80 g/ml G418. After incubation for one day, the medium was removed and the cells were washed twice with 2 ml of Ham's FlO medium supplemented with 1 mg/ml bovine serum albumin (fraction V), 1% L-glutamine, and 80 ,yg/ml G418 (assay medium). At this time the average cell number per well was estimated for each cell line by removing and counting cells from three test wells. The cells were then cultured for 4 hours with 1 ml assay medium containing 100 mlU/ml human recombinant FSH. After incubation, the culture dishes were placed on ice while the culture medium from each well was transferred into separate glass 12 X 75 test tubes. The tubes containing the culture media were placed in a boiling water bath for 10 minutes, then centrifuged at 1100 X g at 4°C. The supernatants were transferred to clean 12 X 75 glass test tubes and stored at -20°C overnight. Progesterone levels were measured using the Serono Diagnostics Progesterone MAIA, product number 12274, distributed by Ciba Corning, Medfield, MA. The assay was done according to the instructions provided by the manufacturer, except that the culture medium samples and the progesterone for the standard curve were diluted in a solution of phosphate buffered saline containing 0.1% bovine serum albumin and 0.6% sodium azide, instead of the dilution buffer provided in the kit. The progesterone for the standard curve was obtained from Cal Biochem (catalog number 5341), and was diluted to a concentration of 15 / -/g/ml in 100% ethanol prior to use. The stock solution was stored at -70°C. The final concentrations of the progesterone standard curve dilutions were the same as those recommended in the assay kit. The diluted progesterone standards were stable at 4°C for one week. Several FSH-treated Yl lines, stably transfected with the human FSH receptor, secreted increased levels of progesterone relative to the controls (the same line not treated with FSH, untransfected Yl cells, Yl cells transfected with CLH3AXSV2NEOhαIVS) . One nonclonal line, Y1HFSHR4-38, was chosen for hormone dose response analyses. The procedure used was the same as that described in the preceding paragraph except that the cells were treated with a range of FSH concentrations, 0-100 miu/ml. Each dose was done in duplicate. The amount of progesterone produced by the FSH-stimulated Yl cells was normalized to 1 X 10 6 cells and plotted versus FSH concentration to generate a dose response curve. The dose response curve is shown in Figure 6. in this particular experiment, a 25-fold increase in progesterone activity was observed at a dose of 20 mlU/ml human recombinant FSH. The linear range was from 2.5 to 20 mlU/ml FSH and the ED50 was 6.4 miu/ml FSH. These results demonstrate that FSH dose dependent increases in progesterone secretion were observed in Yl cells stably transfected with the human recombinant FSH receptor. The human FSH receptor is therefore functionally active when expressed in mouse adrenal Yl cells. Cell populations derived from the CHOHFSHR4Q-13 or Y1HFSHR4-38 cell lines, or similar cell lines, can be used to develop sensitive in vitro bioassays for FSH and FSH- like substances. Other FSH in vitro bioassays which are currently used, such as the granulosa cell aromatase bioassay and the Sertoli cell aromatase bioassay, require the establishment of primary cell cultures from rats each time an assay is performed. For the new Yl cell and CHO cell bioassays, stably transformed continuous cell lines are used. This enables the practice of in vitro bioassay methods superior to the current methods in simplicity, accuracy, and consistency. SEQUENCE LISTING INFORMATION FOR SEQ ID NO: 1 SEQUENCE CHARACTERISTICS (A) LENGTH: 2179 (B) TYPE: Nucleic acid (C) STRANDEDNESS: Double (D) TOPOLOGY: Linear MOLECULE TYPE: cDNA to mRNA ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (F) TISSUE TYPE: Testis IMMEDIATE SOURCE: (A) LIBRARY: λgtll cDNA library, ClonTech #HL1010b (B) CLONE: pHFSHRll-11, pHFSHR15-6 FEATURE: (A) NAME/KEY: protein coding region (B) LOCATION: 75 to 2159 SEQUENCE DESCRIPTION: SEQ ID N0:1: TGTGGAGCTT CTGAGATCTG TGGAGGTTTT TCTCTGCAAA TGCAGGAAGA AATCAGGTGG 60 ATGGATGCAT AATT ATG GCC CTG CTC CTG GTC TCT TTG CTG GCA TTC CTG 110 Met Ala Leu Leu Leu Val Ser Leu Leu Ala Phe Leu -15 -10 AGC TTG GGC TCA GGA TGT CAT CAT CGG ATC TGT CAC TGC TCT AAC AGG 158 Ser Leu Gly Ser Gly Cys His His Arg lie Cys His Cys Ser Asn Arg -5 1 5 10 GTT TTT CTC TGC CAA GAG AGC AAG GTG ACA GAG ATT CCT TCT GAC CTC 206 Val Phe Leu Cys Gin Glu Ser Lys Val Thr Glu lie Pro Ser Asp Leu 15 20 25 CCG AGG AAT GCC ATT GAA CTG AGG TTT GTC CTC ACC AAG CTT CGA GTC 254 Pro Arg Asn Ala lie Glu Leu Arg Phe Val Leu Thr Lys Leu Arg Val 30 35 40 ATC CAA AAA GGT GCA TTT TCA GGA TTT GGG GAC CTG GAG AAA ATA GAG 302 lie Gin Lys Gly Ala Phe Ser Gly Phe Gly Asp Leu Glu Lys lie Glu 45 50 55 ATC TCT CAG AAT GAT GTC TTG GAG GTG ATA GAG GCA GAT GTG TTC TCC 350 He Ser Gin Asn Asp Val Leu Glu Val He Glu Ala Asp Val Phe Ser 60 65 70 75 AAC CTT CCC AAA TTA CAT GAA ATT AGA ATT GAA AAG GCC AAC AAC CTG 398 Asn Leu Pro Lys Leu His Glu He Arg He Glu Lys Ala Asn Asn Leu 80 85 90 CTC TAC ATC AAC CCT GAG GCC TTC CAG AAC CTT CCC AAC CTT CAA TAT 446 Leu Tyr He Asn Pro Glu Ala Phe Gin Asn Leu Pro Asn Leu Gin Tyr 95 100 105 CTG TTA ATA TCC AAC ACA GGT ATT AAG CAC CTT CCA GAT GTT CAC AAG 494 Leu Leu He Ser Asn Thr Gly He Lys His Leu Pro Asp Val His Lys 110 115 120 ATT CAT TCT CTC CAA AAA GTT TTA CTT GAC ATT CAA GAT AAC ATA AAC 542 He His Ser Leu Gin Lys Val Leu Leu Asp He Gin Asp Asn He Asn 125 130 135 ATC CAC ACA ATT GAA AGA AAT TCT TTC GTG GGG CTG AGC TTT GAA AGT 590 He His Thr He Glu Arg Asn Ser Phe Val Gly Leu Ser Phe Glu Ser 140 145 150 155 GTG ATT CTA TGG CTG AAT AAG AAT GGG ATT CAA GAA ATA CAC AAC TGT 638 Val He Leu Trp Leu Asn Lys Asn Gly He Gin Glu He His Asn Cys 160 165 170 GCA TTC AAT GGA ACC CAA CTA GAT GAG CTG AAT CTA AGC GAT AAT AAT 686 Ala Phe Asn Gly Thr Gin Leu Asp Glu Leu Asn Leu Ser Asp Asn Asn 175 180 185 AAT TTA GAA GAA TTG CCT AAT GAT GTT TTC CAC GGA GCC TCT GGA CCA 734 Asn Leu Glu Glu Leu Pro Asn Asp Val Phe His Gly Ala Ser Gly Pro 190 195 200 GTC ATT CTA GAT ATT TCA AGA ACA AGG ATC CAT TCC CTG CCT AGC TAT 782 Val He Leu Asp He Ser Arg Thr Arg He His Ser Leu Pro Ser Tyr 205 210 215 GGC TTA GAA AAT CTT AAG AAG CTG AGG GCC AGG TCG ACT TAC AAC TTA 830 Gly Leu Glu Asn Leu Lys Lys Leu Arg Ala Arg Ser Thr Tyr Asn Leu 220 225 230 235 AAA AAG CTG CCT ACT CTG GAA AAG CTT GTC GCC CTC ATG GAA GCC AGC 878 Lys Lys Leu Pro Thr Leu Glu Lys Leu Val Ala Leu Met Glu Ala Ser 240 245 250 CTC ACC TAT CCC AGC CAT TGC TGT GCC TTT GCA AAC TGG AGA CGG CAA 926 Leu Thr Tyr Pro Ser His Cys Cys Ala Phe Ala Asn Trp Arg Arg Gin 255 260 265 ATC TCT GAG CTT CAT CCA ATT TGC AAC AAA TCT ATT TTA AGG CAA GAA 974 He Ser Glu Leu His Pro He Cys Asn Lys Ser He Leu Arg Gin Glu 270 275 280 GTT GAT TAT ATG ACT CAG ACT AGG GGT CAG AGA TCC TCT CTG GCA GAA 1022 Val Asp Tyr Met Thr Gin Thr Arg Gly Gin Arg Ser Ser Leu Ala Glu 285 290 295 GAC AAT GAG TCC AGC TAC AGC AGA GGA TTT GAC ATG ACG TAC ACT GAG 1070 Asp Asn Glu Ser Ser Tyr Ser Arg Gly Phe Asp Met Thr Tyr Thr Glu 300 305 310 315 TTT GAC TAT GAC TTA TGC AAT GAA GTG GTT GAC GTG ACC TGC TCC CCT 1118 Phe Asp Tyr Asp Leu Cys Asn Glu Val Val Asp Val Thr Cys Ser Pro 320 325 330 AAG CCA GAT GCA TTC AAC CCA TGT GAA GAT ATC ATG GGG TAC AAC ATC 1166 Lys Pro Asp Ala Phe Asn Pro Cys Glu Asp He Met Gly Tyr Asn He 335 340 345 CTC AGA GTC CTG ATA TGG TTT ATC AGC ATC CTG GCC ATC ACT GGG AAC 1214 Leu Arg Val Leu He Trp Phe He Ser He Leu Ala He Thr Gly Asn 350 355 360 ATC ATA GTG CTA GTG ATC CTA ACT ACC AGC CAA TAT AAA CTC ACA GTC 1262 He He Val Leu Val He Leu Thr Thr Ser Gin Tyr Lys Leu Thr Val 365 370 375 CCC AGG TTC CTT ATG TGC AAC CTG GCC TTT GCT GAT CTC TGC ATT GGA 1310 Pro Arg Phe Leu Met Cys Asn Leu Ala Phe Ala Asp Leu Cys He Gly 380 385 390 395 ATC TAC CTG CTG CTC ATT GCA TCA GTT GAT ATC CAT ACC AAG AGC CAA 1358 He Tyr Leu Leu Leu He Ala Ser Val Asp He His Thr Lys Ser Gin 400 405 410 TAT CAC AAC TAT GCC ATT GAC TGG CAA ACT GGG GCA GGC TGT GAT GCT 1406 Tyr His Asn Tyr Ala He Asp Trp Gin Thr Gly Ala Gly Cys Asp Ala 415 420 425 GCT GGC TTT TTC ACT GTC TTT GCC AGT GAG CTG TCA GTC TAC ACT CTG 1454 Ala Gly Phe Phe Thr Val Phe Ala Ser Glu Leu Ser Val Tyr Thr Leu 430 435 440 ACA GCT ATC ACC TTG GAA AGA TGG CAT ACC ATC ACG CAT GCC ATG CAG 1502 Thr Ala He Thr Leu Glu Arg Trp His Thr He Thr His Ala Met Gin 445 450 455 CTG GAC TGC AAG GTG CAG CTC CGC CAT GCT GCC AGT GTC ATG GTG ATG 1550 Leu Asp Cys Lys Val Gin Leu Arg His Ala Ala Ser Val Met Val Met 460 465 470 475 GGC TGG ATT TTT GCT TTT GCA GCT GCC CTC TTT CCC ATC TTT GGC ATC 1598 Gly Trp He Phe Ala Phe Ala Ala Ala Leu Phe Pro He Phe Gly He 480 485 490 AGC AGC TAC ATG AAG GTG AGC ATC TGC CTG CCC ATG GAT ATT GAC AGC 1646 Ser Ser Tyr Met Lys Val Ser He Cys Leu Pro Met Asp He Asp Ser 495 500 505 CCT TTG TCA CAG CTG TAT GTC ATG TCC CTC CTT GTG CTC AAT GTC CTG 1694 Pro Leu Ser Gin Leu Tyr Val Met Ser Leu Leu Val Leu Asn Val Leu 510 515 520 GCC TTT GTG GTC ATC TGT GGC TGC TAT ATC CAC ATC TAC CTC ACA GTG 1742 Ala Phe Val Val He Cys Gly Cys Tyr He His He Tyr Leu Thr Val 525 530 535 CGG AAC CCC AAC ATC GTG TCC TCC TCT AGT GAC ACC AGG ATC GCC AAG 1790 Arg Asn Pro Asn He Val Ser Ser Ser Ser Asp Thr Arg He Ala Lys 540 545 550 555 CGC ATG GCC ATG CTC ATC TTC ACT GAC TTC CTC TGC ATG GCA CCC ATT 1838 Arg Met Ala Met Leu He Phe Thr Asp Phe Leu Cys Met Ala Pro He 560 565 570 TCT TTC TTT GCC ATT TCT GCC TCC CTC AAG GTG CCC CTC ATC ACT GTG 1886 Ser Phe Phe Ala He Ser Ala Ser Leu Lys Val Pro Leu He Thr Val 575 580 585 TCC AAA GCA AAG ATT CTG CTG GTT CTG TTT CAC CCC ATC AAC TCC TGT 1934 Ser Lys Ala Lys He Leu Leu Val Leu Phe His Pro He Asn Ser Cys 590 595 600 GCC AAC CCC TTC CTC TAT GCC ATC TTT ACC AAA AAC TTT CGC AGA GAT 1982 Ala Asn Pro Phe Leu Tyr Ala He Phe Thr Lys Asn Phe Arg Arg Asp 605 610 615 TTC TTC ATT CTG CTG AGC AAG TGT GGC TGC TAT GAA ATG CAA GCC CAA 2030 Phe Phe He Leu Leu Ser Lys Cys Gly Cys Tyr Glu Met Gin Ala Gin 620 625 630 635 ATT TAT AGG ACA GAA ACT TCA TCC ACT GTC CAC AAC ACC CAT CCA AGG 2078 He Tyr Arg Thr Glu Thr Ser Ser Thr Val His Asn Thr His Pro Arg 640 645 650 AAT GGC CAC TGC TCT TCA GCT CCC AGA GTC ACC AAT GGT TCC ACT TAC 2126 Asn Gly His Cys Ser Ser Ala Pro Arg Val Thr Asn Gly Ser Thr Tyr 655 660 665 ATA CTT GTC CCT CTA AGT CAT TTA GCC CAA AAC TAAAACACAA TGTGAAAATG 2179 He Leu Val Pro Leu Ser His Leu Ala Gin Asn 670 675 INFORMATION FOR SEQ ID NO: 2 SEQUENCE CHARACTERISTICS (A) LENGTH: 695 (B) TYPE: Amino acid (D) TOPOLOGY: Linear MOLECULE TYPE: protein FEATURE: (A) NAME/KEY: signal sequence (B) LOCATION: -17 to -1 (C) IDENTIFICATION METHOD: hydrophobic FEATURE: (A) NAME/KEY: putative amino-terminal extracellular domain (B) LOCATION: 1 to 349 (C) IDENTIFICATION METHOD: similarity with other dimeric glycoprotein receptor extracellular domains, hydrophilic FEATURE: (A) NAME/KEY: transmembrane domain (B) LOCATION: 350 to 613 (C) IDENTIFICATION METHOD: similarity to other G protein-coupled receptor transmembrane domains FEATURE: (A) NAME/KEY: putative transmembrane region I (B) LOCATION: 350 to 370 (C) IDENTIFICATION METHOD: similarity to other G protein-coupled receptor transmembrane regions, hydrophobic, about 20-23 amino acids in length FEATURE: (A) NAME/KEY: putative transmembrane region II (B) LOCATION: 382 to 404 (C) IDENTIFICATION METHOD: similarity to other G protein-coupled receptor transmembrane regions, hydrophobic, about 20-23 amino acids in length FEATURE: (A) NAME/KEY: putative transmembrane region III (B) LOCATION: 427 to 448 (C) IDENTIFICATION METHOD: similarity to other G protein-coupled receptor transmembrane regions, hydrophobic, about 20-23 amino acids in length FEATURE: (A) NAME/KEY: putative transmembrane region IV (B) LOCATION: 469 to 491 (C) IDENTIFICATION METHOD: similarity to other G protein-coupled receptor transmembrane regions, hydrophobic, about 20-23 amino acids in length FEATURE: (A) NAME/KEY: putative transmembrane region V (B) LOCATION: 512 to 533 (C) IDENTIFICATION METHOD: similarity to other G protein-coupled receptor transmembrane regions, hydrophobic, about 20-23 amino acids in length FEATURE: (A) NAME/KEY: putative transmembrane region VI (B) LOCATION: 557 to 580 (C) IDENTIFICATION METHOD: similarity to other G protein-coupled receptor transmembrane regions, hydrophobic, about 20-23 amino acids in length FEATURE: (A) NAME/KEY: putative transmembrane region VII (B) LOCATION: 592 to 613 (C) IDENTIFICATION METHOD: similarity to other G protein-coupled receptor transmembrane regions, hydrophobic, about 20-23 amino acids in length FEATURE: (A) NAME/KEY: putative carboxy-terminal intracellular domain (B) LOCATION: 614 to 678 SEQUENCE DESCRIPTION: SEQ ID NO:2: Met Ala Leu Leu Leu Val Ser Leu Leu Ala Phe Leu Ser Leu Gly Ser -15 -10 -5 Gly Cys His His Arg He Cys His Cys Ser Asn Arg Val Phe Leu Cys 1 5 10 15 Gin Glu Ser Lys Val Thr Glu He Pro Ser Asp Leu Pro Arg Asn Ala 20 25 30 He Glu Leu Arg Phe Val Leu Thr Lys Leu Arg Val He Gin Lys Gly 35 40 45 Ala Phe Ser Gly Phe Gly Asp Leu Glu Lys He Glu He Ser Gin Asn 50 55 60 Asp Val Leu Glu Val He Glu Ala Asp Val Phe Ser Asn Leu Pro Lys 65 70 75 Leu His Glu He Arg He Glu Lys Ala Asn Asn Leu Leu Tyr He Asn 80 85 90 95 Pro Glu Ala Phe Gin Asn Leu Pro Asn Leu Gin Tyr Leu Leu He Ser 100 105 110 Asn Thr Gly He Lys His Leu Pro Asp Val His Lys He His Ser Leu 115 120 125 Gin Lys Val Leu Leu Asp He Gin Asp Asn He Asn He His Thr He 130 135 140 Glu Arg Asn Ser Phe Val Gly Leu Ser Phe Glu Ser Val He Leu Trp 145 150 155 Leu Asn Lys Asn Gly He Gin Glu He His Asn Cys Ala Phe Asn Gly 160 165 170 175 Thr Gin Leu Asp Glu Leu Asn Leu Ser Asp Asn Asn Asn Leu Glu Glu 180 185 190 Leu Pro Asn Asp Val Phe His Gly Ala Ser Gly Pro Val He Leu Asp 195 200 205 He Ser Arg Thr Arg He His Ser Leu Pro Ser Tyr Gly Leu Glu Asn 210 215 220 Leu Lys Lys Leu Arg Ala Arg Ser Thr Tyr Asn Leu Lys Lys Leu Pro 225 230 235 Thr Leu Glu Lys Leu Val Ala Leu Met Glu Ala Ser Leu Thr Tyr Pro 240 245 250 255 Ser His Cys Cys Ala Phe Ala Asn Trp Arg Arg Gin He Ser Glu Leu 260 265 270 His Pro He Cys Asn Lys Ser He Leu Arg Gin Glu Val Asp Tyr Met 275 280 285 Thr Gin Thr Arg Gly Gin Arg Ser Ser Leu Ala Glu Asp Asn Glu Ser 290 295 300 Ser Tyr Ser Arg Gly Phe Asp Met Thr Tyr Thr Glu Phe Asp Tyr Asp 305 310 315 Leu Cys Asn Glu Val Val Asp Val Thr Cys Ser Pro Lys Pro Asp Ala 320 325 330 335 Phe Asn Pro Cys Glu Asp He Met Gly Tyr Asn He Leu Arg Val Leu 340 345 350 He Trp Phe He Ser He Leu Ala He Thr Gly Asn He He Val Leu 355 360 365 Val He Leu Thr Thr Ser Gin Tyr Lys Leu Thr Val Pro Arg Phe Leu 370 375 380 Met Cys Asn Leu Ala Phe Ala Asp Leu Cys He Gly He Tyr Leu Leu 385 390 395 Leu He Ala Ser Val Asp He His Thr Lys Ser Gin Tyr His Asn Tyr 400 405 410 415 Ala He Asp Trp Gin Thr Gly Ala Gly Cys Asp Ala Ala Gly Phe Phe 420 425 430 Thr Val Phe Ala Ser Glu Leu Ser Val Tyr Thr Leu Thr Ala He Thr 435 440 445 Leu Glu Arg Trp His Thr He Thr His Ala Met Gin Leu Asp Cys Lys 450 455 460 Val Gin Leu Arg His Ala Ala Ser Val Met Val Met Gly Trp He Phe 465 470 475 Ala Phe Ala Ala Ala Leu Phe Pro He Phe Gly He Ser Ser Tyr Met 480 485 490 495 Lys Val Ser He Cys Leu Pro Met Asp He Asp Ser Pro Leu Ser Gin 500 505 510 Leu Tyr Val Met Ser Leu Leu Val Leu Asn Val Leu Ala Phe Val Val 515 520 525 He Cys Gly Cys Tyr He His He Tyr Leu Thr Val Arg Asn Pro Asn 530 535 540 He Val Ser Ser Ser Ser Asp Thr Arg He Ala Lys Arg Met Ala Met 545 550 555 Leu He Phe Thr Asp Phe Leu Cys Met Ala Pro He Ser Phe Phe Ala 560 565 570 575 Ile Ser Ala Ser Leu Lys Val Pro Leu He Thr Val Ser Lys Ala Lys 580 585 590 He Leu Leu Val Leu Phe His Pro He Asn Ser Cys Ala Asn Pro Phe 595 600 605 Leu Tyr Ala He Phe Thr Lys Asn Phe Arg Arg Asp Phe Phe He Leu 610 615 620 Leu Ser Lys Cys Gly Cys Tyr Glu Met Gin Ala Gin He Tyr Arg Thr 625 630 635 Glu Thr Ser Ser Thr Val His Asn Thr His Pro Arg Asn Gly His Cys 640 645 650 655 Ser Ser Ala Pro Arg Val Thr Asn Gly Ser Thr Tyr He Leu Val Pro 660 665 670 Leu Ser His Leu Ala Gin Asn 675

Claims: We claim: 1. Essentially pure human follicle stimulating hormone (FSH) receptor or a fragment or mutant thereof which binds FSH. 2. The FSH receptor of claim 1 comprising the amino acid sequence 1 to 678 shown in Sequence ID No:2. 3. The FSH receptor of claim 2 wherein the cytoplasmic domain is deleted. 4. The FSH receptor of claim 3 wherein the transmembrane domain is deleted. 5. The FSH receptor of claim 1 comprising the amino acid sequence 1 to 349 shown in Sequence ID No:2, or a substantial portion thereof with substantially the same FSH-binding characteristics. 6. Isolated DNA encoding human FSH receptor or a fragment or mutant thereof which binds FSH. 7. The isolated DNA of claim 6 comprising the nucleotide sequence shown in Sequence ID No:l. 8. The isolated DNA of claim 7 wherein the nucleotide sequence encoding the cytoplasmic domain of the FSH receptor is deleted. 9. The isolated DNA of claim 8 wherein the nucleotide sequence encoding the transmembrane domain of the FSH receptor is deleted. 10. The isolated DNA of claim 6 comprising a nucleotide sequence encoding the amino acid sequence 1 to 349 shown in Sequence ID No:2, or a substantial portion thereof with substantially the same FSH-binding characteristics. 11. A recombinant expression vector comprising the DNA of claim 6, 7, 8, 9, or 10. 12. A cell transfected with the expression vector of claim 11. 13. The cell of claim 12 which is a mammalian cell. 14. A method of producing human FSH receptor, or a fragment or mutant thereof which binds FSH, which comprises culturing the cell of claim 12 in a nutrient medium and recovering the receptor therefrom. 15. The method of claim 14 wherein the cell is a mammalian cell. 16. A pharmaceutical composition comprising human FSH receptor, or a fragment or mutant thereof which binds FSH, and a pharmaceutically acceptable carrier. 17. The composition of claim 16 comprising a fragment of human FSH receptor, said fragment comprising the amino- terminal extracellular domain of human FSH receptor or a substantial portion thereof with substantially the same FSH-binding characteristics. 18. In a method of assaying human FSH using an FSH receptor, the improvement wherein said FSH receptor is essentially pure human FSH receptor or a fragment or mutant thereof which binds FSH. 19. The method of claim 18 wherein a fragment of human FSH receptor is used, said fragment comprising the amino- terminal extracellular domain of human FSH receptor or a substantial portion thereof with substantially the same FSH-binding characteristics. 20. A method of reducing endogenous FSH bioactivity in a patient comprising administering to said patient a pharmaceutical composition comprising essentially pure human FSH receptor, or a fragment or mutant thereof which binds FSH, in an amount effective to reduce the endogenous FSH bioactivity. 21. A method of preventing follicle growth and maturation in a female patient comprising administering to said patient a pharmaceutical composition comprising essentially pure human FSH receptor or a fragment or a mutant thereof which binds FSH, in an amount effective to prevent follicle growth and maturation. 22. A method of preventing spermatogenesis in a male patient comprising administering to said patient a pharmaceutical composition comprising essentially pure human FSH receptor or a fragment or a mutant thereof which binds FSH, in an amount effective to prevent spermatogenesis. 23. The method of claim 20, 21, or 22 wherein said composition comprises a fragment of human FSH receptor, said fragment comprising the amino-terminal extracellular domain of human FSH receptor or a substantial portion thereof with substantially the same FSH-binding characteristics. 24. A method of assaying a sample for substances having FSH bioactivity which comprises culturing a recombinant cell line in the presence of said sample, wherein said recombinant cell line is adapted to express human FSH receptor and produce a measurable biological response in the presence of FSH, and measuring any such biological response.

Inventors: CHENG SHIRLEY VUI YEN, KELTON CHRISTIE ANN, NUGENT NOREEN PATRICE, SCHWEICKHARDT RENE LYNN, CHENG, SHIRLEY, VUI, YEN, KELTON, CHRISTIE, ANN, NUGENT, NOREEN, PATRICE, SCHWEICKHARDT, RENE, LYNN
Applicants: APPLIED RESEARCH SYSTEMS, APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
Application year: 1992
Main classification: A61K37
IPC codes: A61K38, A61P5, A61P13, A61P15, C07K14, C12N5, C12N15, C12P21, C12R1, G01N33